Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: RDY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.95
1 Year Target Price $14.95
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.41% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.14B USD | Price to earnings Ratio 18.23 | 1Y Target Price 14.95 |
Price to earnings Ratio 18.23 | 1Y Target Price 14.95 | ||
Volume (30-day avg) 4 | Beta 0.33 | 52 Weeks Range 12.18 - 16.07 | Updated Date 10/25/2025 |
52 Weeks Range 12.18 - 16.07 | Updated Date 10/25/2025 | ||
Dividends yield (FY) 0.63% | Basic EPS (TTM) 0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.99% | Operating Margin (TTM) 20.5% |
Management Effectiveness
Return on Assets (TTM) 9.71% | Return on Equity (TTM) 17.71% |
Valuation
Trailing PE 18.23 | Forward PE 18.28 | Enterprise Value 11493649015 | Price to Sales(TTM) 0.04 |
Enterprise Value 11493649015 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 10.39 | Shares Outstanding 832515335 | Shares Floating 591382842 |
Shares Outstanding 832515335 | Shares Floating 591382842 | ||
Percent Insiders - | Percent Institutions 13.65 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddy's Laboratories Ltd. was founded in 1984 by Dr. Kallam Anji Reddy in Hyderabad, India. Initially focused on manufacturing active pharmaceutical ingredients (APIs), it evolved into a global pharmaceutical company with a broad portfolio of generic and proprietary products.
Core Business Areas
- Generics: Manufactures and markets generic pharmaceuticals across various therapeutic areas. This segment is a major revenue driver.
- Pharmaceutical Services & Active Ingredients (PSAI): Provides custom pharmaceutical services and manufactures APIs for both internal consumption and external sale.
- Proprietary Products: Develops and commercializes innovative and differentiated products, including biosimilars and novel chemical entities.
Leadership and Structure
The company is led by a CEO and a management team responsible for various functions. The organizational structure includes business units focused on specific geographies and product segments. Currently, G.V. Prasad serves as the Co-Chairman & MD of the company.
Top Products and Market Share
Key Offerings
- Omeprazole: A generic proton pump inhibitor. Competitors include Teva Pharmaceuticals, Mylan (now Viatris), and other generic manufacturers. Market share varies by region and specific formulation.
- Ibuprofen: A generic nonsteroidal anti-inflammatory drug (NSAID). Competitors include Teva Pharmaceuticals, Mylan (now Viatris), and other generic manufacturers. Market share varies by region and specific formulation.
- Doxorubicin: Chemotherapy medication used to treat cancer. Competitors include Teva Pharmaceuticals, Mylan (now Viatris), and other generic manufacturers. Market share varies by region and specific formulation.
- Biosimilars: Dr. Reddy's has developed and launched biosimilars of several blockbuster drugs. Competitors include Sandoz, Amgen, and Biocon. Market share varies based on specific biosimilar and region.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, increasing regulatory scrutiny, and a growing demand for affordable medicines. Generic drugs account for a large percentage of prescriptions filled. Biosimilars are also gaining traction.
Positioning
Dr. Reddy's is positioned as a vertically integrated pharmaceutical company with a strong presence in both generics and proprietary products. Its competitive advantages include its manufacturing capabilities, R&D expertise, and global reach.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be worth over $1 trillion. Dr. Reddy's is positioned to capture a significant share of this market through its diversified product portfolio and geographic presence.
Upturn SWOT Analysis
Strengths
- Strong presence in generics market
- Vertically integrated operations
- Expanding biosimilars portfolio
- R&D capabilities
- Global reach
Weaknesses
- Reliance on generic drugs with price erosion
- Exposure to regulatory risks
- Limited presence in innovative drugs
- Dependence on key markets
Opportunities
- Growth in emerging markets
- Increasing demand for biosimilars
- Strategic acquisitions
- Partnerships with other pharmaceutical companies
Threats
- Intense competition from generic manufacturers
- Pricing pressure from governments and payers
- Patent expirations
- Regulatory changes
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- MYL
Competitive Landscape
Dr. Reddy's competes with global generic manufacturers on price, quality, and product availability. It also competes with innovator companies in the biosimilars and proprietary products segments.
Growth Trajectory and Initiatives
Historical Growth: Discuss Dr. Reddyu2019s Laboratories Ltd ADR's growth trends over the past years.
Future Projections: Provide projections for Dr. Reddyu2019s Laboratories Ltd ADR's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Dr. Reddyu2019s Laboratories Ltd ADR.
Summary
Dr. Reddy's is a robust pharmaceutical company with a strong generic business. Its investments in biosimilars and proprietary products are showing promise. Regulatory risks and intense price competition within the generics industry pose challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Industry analysis reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are approximate and may vary by region and product.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27811 | Website https://www.drreddys.com |
Full time employees 27811 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.